The Patent Finder

Poxel S.A.

17 patents currently held · Updated Nov 21, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
Sep 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 26, 2027
    The maintenance fee for Methods of synthesizing enantiopure deuterium-enriched pioglitazone (US 11,767,317) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
  • 2 fees due Sep 5, 2027

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,925,175Deuterium-enriched pioglitazone
In force
 · USPTO record
In forceUSPTO record
US 10,940,143Deuterium-enriched pioglitazone
In force
 · USPTO record
In forceUSPTO record
US 8,980,828Combination of Insulin with Triazine Derivatives and Its Use for Treating Diabetes
In force
 · Medium confidence
In forceMedium confidence
US 11,918,567Deuterium-enriched pioglitazone
In force
 · USPTO record
In forceUSPTO record
US 8,722,710Deuterium-enriched pioglitazone
In force
 · USPTO record
In forceUSPTO record
US 8,969,5815-Deutero-2,4-Thiazolidinedione Derivatives and Compositions Comprising and Methods of Using the Same
In force
 · High confidence
In forceHigh confidence
US 9,416,1175-Deutero-2,4-Thiazolidinedione Derivatives and Compositions Comprising and Methods of Using the Same
In force
 · High confidence
In forceHigh confidence
US 9,833,4455-Deutero-2,4-Thiazolidinedione Derivatives and Compositions Comprising and Methods of Using the Same
In force
 · High confidence
In forceHigh confidence
US 10,265,3055-Deutero-2,4-Thiazolidinedione Derivatives and Compositions Comprising and Methods of Using the Same
In force
 · High confidence
In forceHigh confidence
US 11,123,3365-Deutero-2,4-Thiazolidinedione Derivatives and Compositions Comprising and Methods of Using the Same
In force
 · High confidence
In forceHigh confidence
10 of 17 patents shown.
Pro members see all 17.
Pro members: see all 17 patents
Also on record, not counted in the 17: 2 patents in force now held by others · 5 lapsed for an unpaid fee · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 abandoned · 5 no status recorded

Showing 1 to 9 of 9, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/088,680Methods of Treating Neurological, Metabolic, and Other Disorders Using Enantiopure Deuterium-Enriched PioglitazoneMar 24, 2025Abandoned
17/882,949Aug 8, 2022No status recorded
17/709,798Crystalline Forms of Deuterium-Enriched PioglitazoneMar 31, 2022Abandoned
17/394,589Methods of Treating Neurological, Metabolic, and Other Disorders Using Enantiopure Deuterium-Enriched PioglitazoneAug 5, 2021Abandoned
17/094,942Nov 11, 2020No status recorded
16/710,103Dec 11, 2019No status recorded
16/567,445Sep 11, 2019No status recorded
16/541,337Aug 15, 2019No status recorded
14/063,530Combination of Triazine Derivatives and Insulin SensitisersOct 25, 2013Abandoned
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited